Sarepta Therapeutics saw the highest growth of 174% in patent filings and 232% in grants in March in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 124% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Sarepta Therapeutics‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Sarepta Therapeutics has been focused on protecting inventions in South Korea(KR) with nine publications in Q1 2024

The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 23% filings and 30% grants. The South Korea(KR), Japan(JP), European Patent Office(EPO), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Sarepta Therapeutics is filings its patents. Among the top granted patent authorities, Sarepta Therapeutics has 30% of its grants in South Korea(KR), 30% in United States(US) and 10% in European Patent Office(EPO).

F. Hoffmann-La Roche and Ionis Pharmaceuticals could be the strongest competitors for Sarepta Therapeutics

In terms of grant share, Sarepta Therapeutics stands in sixth position among its competitors. F. Hoffmann-La Roche and Ionis Pharmaceuticals secured the top positions according to recent patent publication data.

Patents related to rare diseases and climate change lead Sarepta Therapeutics's portfolio

Sarepta Therapeutics has the highest number of patents in rare diseases followed by, climate change and cell & gene therapy. For rare diseases, nearly 64% of patents were filed and 67% of patents were granted in Q1 2024.

Muscular dystrophy related patents lead Sarepta Therapeutics portfolio followed by duchenne muscular dystrophy, and bacterial infections

Sarepta Therapeutics has highest number of patents in muscular dystrophy followed by duchenne muscular dystrophy, bacterial infections, viral infections, and central precocious puberty. For muscular dystrophy, nearly 49% of patents were filed and 29% of patents were granted in Q1 2024.

For comprehensive analysis of Sarepta Therapeutics's filings and grants, buy the databook here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.